GT Biopharma to Participate in the 38th Annual Roth Conference
Rhea-AI Summary
GT Biopharma (NASDAQ: GTBP) announced that Michael Breen, Executive Chairman and CEO, will participate in the 38th Annual Roth Conference in Laguna Niguel, CA, March 22-24, 2026.
Presentation is scheduled for Tuesday, March 24, 2026 at 1:30 PM PDT; the company will also be available for one-on-one investor meetings by contacting a Roth representative.
Positive
- None.
Negative
- None.
News Market Reaction – GTBP
In the Mar 11 session, GTBP gained 5.67%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.5% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Full-year earnings | Positive | -2.3% | Reported 2025 results, cash of $7M and runway into Q4 2026. |
| Feb 17 | Investor conference | Neutral | -1.4% | Announced participation in Centurion One Toronto growth conference with 1x1 meetings. |
| Feb 03 | IND clearance | Positive | +2.3% | FDA cleared IND for GTB-5550, enabling Phase 1 basket trial mid-2026. |
| Jan 15 | IND submission | Positive | +10.6% | Submitted IND for GTB-5550 with planned Phase 1 basket trial design. |
| Nov 19 | Pipeline update | Positive | +3.7% | Outlined advancing Phase 1 trials and near-term NK engager milestones into 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Most recent GTBP news with clearly positive clinical or pipeline catalysts saw aligned positive moves, while the latest earnings/cash runway update drew a negative reaction.
Over the last several months, GTBP has focused on advancing its TriKE® NK cell engager pipeline and shoring up liquidity. Clinical updates for GTB-5550 and GTB-3650, including IND clearance and trial progress, previously coincided with gains of 2.29%, 3.74%, and 10.61%. In contrast, the full-year 2025 results and cash runway update on Mar 2, 2026 saw a 2.3% decline. Today’s conference participation fits the pattern of routine investor outreach following key regulatory and earnings disclosures.
Key Terms
natural killer (nk) cell medical
nk cell engager medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, CALIFORNIA, March 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, will participate in the 38th Annual Roth Conference being held March 22-24, 2026 in Laguna Niguel, CA.
38th Annual Roth Conference
Format: Presentation and 1x1 investor meetings
Presentation Date: Tuesday, March 24th, 2026
Time: 1:30 PM PDT
The Company will be available for one-on-one meetings at the conference. If interested, please contact your Roth representative.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit gtbiopharma.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE® is a registered trademark owned by GT Biopharma, Inc.
Investor Relations Contact:
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
212-915-2577
LinkedIn |Facebook |X |Instagram | YouTube
